Enzalutamide, a potent second-generation inhibitor of AR signalling, curtails the proliferation of PCa cells and extends the survival of CRPC patients by impeding the nuclear translocation of activated AR [3, 53]. This evidence concerns the gene AR and posterior cortical atrophy.